Spironolactone does reduce testosterone production, but that is only part of its anti-androgen story. The drug also blocks testosterone from binding to its receptor and interferes with the enzymes that build testosterone in the first place. In practice, however, the drop in circulating testosterone levels varies considerably depending on the person’s sex, dose, and what you measure. Some studies in women find a clear decline in total testosterone; others find no measurable change at all, even while the drug visibly improves androgen-driven symptoms like acne and excess hair growth. That disconnect is what makes spironolactone more interesting, and more confusing, than a simple “yes” suggests.
How Spironolactone Interferes With Testosterone
Spironolactone was originally designed as a potassium-sparing diuretic, derived from progesterone and developed to treat high blood pressure and fluid retention. Its anti-androgen properties were discovered later, largely because of that structural similarity to progesterone, which allows it to interact with hormone receptors it was never meant to touch.1Journal of Natural Sciences. A Literature Review of the Pharmacokinetics, Pharmacodynamics, and Possible Uses of Spironolactone The drug works against testosterone through at least three distinct pathways, and understanding which one matters most depends on the clinical situation.
First, spironolactone directly competes with testosterone and its more potent form, dihydrotestosterone (DHT), for access to the androgen receptor. It physically blocks the receptor so androgens cannot activate it. Research on human sex steroid receptors found that spironolactone binds to the androgen receptor competitively, though with roughly one-tenth the affinity of DHT.2The Journal of Clinical Endocrinology & Metabolism. Interaction of Digitalis and Spironolactone with Human Sex Steroid Receptors – Section: Abstract That may sound weak, but therapeutic doses push enough drug into the system to matter at the tissue level.
Second, spironolactone suppresses the enzymes responsible for testosterone synthesis. Animal studies found that daily dosing caused a 40 to 90 percent decrease in the level of a key enzyme complex (cytochrome P-450) in testicular tissue, along with a corresponding loss in the activity of 17α-hydroxylase, an enzyme essential for building testosterone.3Endocrinology. Spironolactone and Testicular Cytochrome P-450: Decreased Testosterone Formation in Several Species and Changes in Hepatic Drug Metabolism That is a steep reduction in the cellular machinery the body needs to manufacture the hormone.
Third, the drug’s metabolites appear to carry their own anti-androgen punch. Over 80 percent of spironolactone is irreversibly converted to a compound called canrenone, which itself shows relatively modest anti-androgen activity in lab assays. Researchers have suspected that other minor metabolites, not yet fully identified, may have far higher affinity for the androgen receptor or persist in the bloodstream much longer than canrenone alone.4PubMed. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay In other words, we still do not fully understand all the ways spironolactone exerts its anti-androgen effects.
What Actually Happens to Testosterone Levels in Women
If you look only at total testosterone numbers on a blood test, the picture in women is surprisingly inconsistent. Some trials show a clear drop. A study comparing spironolactone with metformin in women with polycystic ovary syndrome (PCOS) found that testosterone decreased in both treatment groups.5The Journal of Clinical Endocrinology & Metabolism. Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study – Section: Abstract A dose-comparison study in women with excess hair growth also found that total testosterone fell significantly at both low and high doses.6PubMed. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women – Section: Abstract
But other studies tell a different story. A long-term trial following women with hirsutism for up to 12 months found that testosterone levels did not change at all with spironolactone, even though the women’s symptoms improved.7PubMed. Spironolactone as a single agent for long-term therapy of hirsute patients – Section: RESULTS Similarly, a study of women treated for acne found clinically significant skin improvement in about 85 percent of patients, yet mean total testosterone did not budge.8PubMed. Effects and side-effects of spironolactone therapy in women with acne – Section: RESULTS And a recent systematic review of low-dose, short-term spironolactone for PCOS symptoms found no statistically significant difference in testosterone reduction compared to metformin alone.9PubMed. Short-Term, Low-Dose Spironolactone for Treatment of Hyperandrogenic Symptoms of Polycystic Ovary Syndrome-A Systematic Review – Section: RESULTS
This discrepancy is a source of real confusion for patients who expect their lab numbers to reflect how they feel. The resolution lies in the fact that spironolactone’s receptor-blocking activity can produce clinical benefit even when the total amount of testosterone circulating in the blood stays the same. If the drug is occupying the androgen receptor, testosterone loses its ability to drive symptoms at the tissue level regardless of what the blood test says.
The Free Testosterone Complication
Things get even more nuanced when you look beyond total testosterone to its bioavailable fractions. Most testosterone in the blood is bound to proteins, especially sex hormone-binding globulin (SHBG). Only the unbound (“free”) fraction and the loosely bound albumin fraction are considered active in tissues.
A study of hirsute women found that while total testosterone did not change with spironolactone, there was a shift in how it was distributed: SHBG-bound testosterone decreased, and the free and albumin-bound fractions actually increased.10PubMed. The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women – Section: Abstract The researchers concluded that measuring testosterone fractions may not be clinically useful during spironolactone therapy, because the numbers can move in ways that seem to contradict the drug’s beneficial effects. This is a good example of why clinicians tend to monitor symptoms rather than chasing testosterone levels in women taking spironolactone.
A separate study in women with anovulation noted that SHBG levels tended to rise during spironolactone treatment, though the increase was not statistically significant.11PubMed. Spironolactone therapy for hyperandrogenic anovulatory women–clinical and endocrinological study The dose-comparison study mentioned earlier also found that while total testosterone fell, unbound testosterone was unaltered.6PubMed. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women – Section: Abstract Taken together, these findings suggest that spironolactone’s hormonal effects on blood levels are neither straightforward nor the whole story of how it works.
Adrenal and Ovarian Testosterone Sources
Women produce androgens from two places: the ovaries and the adrenal glands. Spironolactone appears to affect both, but not symmetrically. Research on adrenal steroidogenesis found that spironolactone decreased the adrenal output of androstenedione (a precursor to testosterone) but did not alter levels of DHEA or its sulfated form, DHEA-S.12PubMed. The effects of spironolactone on adrenal steroidogenesis in hirsute women This matters because DHEA-S is often used as a clinical marker for adrenal androgen production, and a normal DHEA-S level during spironolactone therapy does not mean the adrenals are unaffected.
Studies have confirmed that both adrenal and ovarian androgen production, as measured by circulating hormone levels, can be diminished by the drug.13PubMed. The endocrine effects of spironolactone used as an antiandrogen However, the degree of suppression from each source varies from person to person, which is one reason different women respond differently to the same dose.
Effects in Men and Gynecomastia
For men, spironolactone’s anti-androgen effects are generally unwanted. The drug was originally prescribed to men for heart failure and resistant hypertension, and its interference with testosterone pathways produces side effects that have historically limited its use in this population. The most recognizable is gynecomastia, the development of breast tissue. Case reports document painful breast swelling appearing after months of treatment, consistent with reduced androgen signaling and a relative increase in estrogen activity.14PubMed Central. Spironolactone-Induced Unilateral Gynecomastia – Section: Abstract
In boys with delayed puberty, spironolactone has been shown to disrupt the feedback loop between the gonads and the pituitary gland. When spironolactone blocked androgen action, the pituitary interpreted the reduced signal as low testosterone and responded by increasing luteinizing hormone (LH) output by about 60 percent.15PubMed. Spironolactone stimulation of gonadotropin secretion in boys with delayed adolescence That pituitary response is relevant for adults too: the body tries to compensate for the androgen blockade by ramping up signals to produce more testosterone, which can partially offset the drug’s suppressive effects on testosterone levels. This is part of why blood testosterone levels in men on spironolactone sometimes do not fall as much as you might expect from the drug’s mechanism.
A broader review of spironolactone’s endocrine effects confirmed that the drug affects both gonadal and adrenal steroidogenesis, elevates gonadotropin levels in children, and acts as an antiandrogen at the tissue level.16PubMed. Spironolactone and endocrine dysfunction Eplerenone, a newer mineralocorticoid receptor antagonist, was developed partly to avoid these hormonal side effects and is often preferred for men who need aldosterone blockade without the anti-androgen baggage.
Spironolactone in Gender-Affirming Hormone Therapy
Spironolactone is the most commonly prescribed anti-androgen for transgender women in the United States, typically used alongside estradiol. Its appeal lies in its availability, low cost, and decades of clinical familiarity. But the evidence on how effectively it actually lowers testosterone in this context is more sobering than its popularity might suggest.
A randomized controlled trial comparing spironolactone with cyproterone acetate (a stronger anti-androgen used widely outside the U.S.) found a striking difference after 12 weeks of feminizing hormone therapy. The cyproterone group saw a much larger drop in testosterone, and 90 percent of those patients achieved female-range testosterone levels (below 50 ng/dL), compared with just 19 percent in the spironolactone group.17The Journal of Sexual Medicine. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial – Section: RESULTS That is a large gap in raw testosterone suppression.
A systematic review examining multiple anti-androgens in transgender women reached a similar conclusion: cyproterone acetate, medroxyprogesterone acetate, and leuprolide all appeared more effective than spironolactone at lowering serum testosterone. However, the same review raised an important caveat: because spironolactone blocks the androgen receptor directly, it is unclear whether the difference in blood testosterone levels translates into meaningful differences in feminization outcomes like breast development or skin changes.18PubMed. A systematic review of antiandrogens and feminization in transgender women In other words, a higher number on a lab report does not necessarily mean a better experience of feminization, because the drug may be neutralizing much of what testosterone can do even while leaving some circulating in the blood.
This distinction between suppressing testosterone levels and suppressing testosterone’s effects is arguably the central theme of spironolactone pharmacology. The drug is not primarily a testosterone-lowering agent; it is primarily an androgen blocker that also happens to reduce testosterone production to varying degrees.
Potassium and Other Safety Considerations
Because spironolactone blocks aldosterone receptors in the kidney, it causes the body to retain potassium. In most young, healthy women prescribed it for acne or hirsutism, this is manageable. But the risk of elevated potassium (hyperkalemia) climbs with age, because kidney function naturally declines over time. A retrospective study of women with acne found that hyperkalemia during spironolactone use was not unexpected in otherwise healthy older women and warrants ongoing monitoring. Current prescribing guidelines call for checking potassium levels within a week of starting the drug or changing the dose, and regularly afterward.19PubMed Central. Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR program – Section: Discussion
Beyond potassium, spironolactone can affect other hormones in the body. Research in women with PCOS found that serum estradiol levels and endometrial thickness both decreased during treatment, and women who experienced intermenstrual bleeding had significantly lower estradiol values than those who did not.20PubMed Central. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI – Section: RESULTS Irregular menstrual bleeding is one of the more common complaints women report on the drug, and it often drives discontinuation even when the drug is otherwise working well for skin or hair symptoms.
Pregnancy and Fetal Risk
Spironolactone is not recommended during pregnancy, specifically because of its anti-androgen activity. During fetal development, testosterone plays a critical role in the formation of male genitalia. A drug that blocks androgen receptors and suppresses testosterone production could interfere with the sexual development of a male fetus.21PubMed Central. Case report: A pregnant woman accidental treated with spironolactone in mid-gestation – Section: Abstract This concern has been consistent across clinical guidelines, and the anti-androgenic mechanism that makes spironolactone therapeutically useful is the same one that makes it dangerous in this setting.22PubMed Central. Primary aldosteronism in pregnancy Women of reproductive age taking the drug are typically advised to use reliable contraception throughout treatment.
Topical Spironolactone and Systemic Hormones
Given the systemic hormonal effects of oral spironolactone, researchers have investigated whether applying it to the skin could deliver anti-androgen benefits locally without affecting the rest of the body. A study measuring plasma testosterone, DHT metabolites, salivary testosterone (which reflects the free, active fraction), and urinary canrenone levels after topical application found no changes in any of those hormone markers. Plasma canrenone, the primary metabolite, was undetectable throughout 72 hours of topical treatment. The researchers concluded that topically administered spironolactone appears to act only through local skin impregnation without systemic absorption.23PubMed. Lack of endocrine systemic side effects after topical application of spironolactone in man
This is a genuinely appealing idea for people who want the skin benefits without the hormonal disruption, menstrual irregularity, or potassium concerns. Topical spironolactone formulations have become available, marketed mainly for androgenetic hair loss and acne. The trade-off is that local-only action means no systemic androgen blockade, so conditions driven by circulating androgens rather than local skin sensitivity would not benefit. For someone whose primary concern is facial acne or scalp hair thinning, that may be perfectly adequate. For someone with PCOS-driven hirsutism across large areas of the body, it probably is not.